#United States #New York #Securities Law #Actinium Pharmaceuticals #ATNM

Actinium Pharmaceuticals Lawsuit Overview

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is currently embroiled in a significant legal battle regarding securities law violations that have prompted a notice from The Gross Law Firm, urging affected shareholders to take action. This article aims to inform investors about the allegations and their potential rights in this matter.

The Allegations

The lawsuit, which concerns transactions that took place between October 31, 2022, and August 2, 2024, claims that during this period, the company issued misleading statements regarding its products and operational status. Specifically, the complaint suggests that:
1. Inadequate Data Submission: Actinium's data from the Phase 3 Sierra trial may not meet the FDA’s strict guidelines necessary for approval of its targeted radiotherapy, Iomab-B, which could hinder the product's acceptance.
2. Misleading Long-Term Follow-ups: Additional analyses provided to the FDA, intended to demonstrate a positive trend in overall survival rates, were likely insufficient to alleviate the concerns raised by the initial Sierra Trial data.
3. Approval Concerns: Due to the previous points, there is a reasonable expectation that the FDA will either refuse to review the Iomab-B Biologics License Application (BLA) or will not approve the application in its current format.
4. Misrepresentation of Company Status: These potential issues could render prior statements by the company regarding its business outlook misleading and unsubstantiated.

Deadline for Action

Shareholders who believe they have suffered losses as a result of these allegations are encouraged to act quickly. The deadline for registering as a participant in this class action is May 27, 2025. Registration is pivotal because it not only secures one's involvement but also keeps shareholders informed through a portfolio monitoring software that provides case updates.

Next Steps for Shareholders

If you purchased shares during the class period, it is advisable to contact The Gross Law Firm to explore the possibility of being appointed a lead plaintiff. However, involvement in the class action does not necessitate an appointment to partake in any recovery.

How to Register

Investors can register easily through the provided links for the Actinium Pharmaceuticals, Inc. Loss Submission Form. This action initiates the process of protecting their rights as shareholders.

Why Choose The Gross Law Firm?

The Gross Law Firm is a highly regarded national law firm specializing in class actions. Their commitment lies in defending the rights of investors who have encountered financial losses due to corporate misconduct. The firm focuses on ensuring companies adhere to ethical business practices and strives for accountability in the industry. They operate on a contingency basis, meaning there are no upfront costs for involved shareholders.

Contact Information

For further details, affected shareholders can reach out via the following contact information:
The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY, 10018
Phone: (646) 453-8903
Email: [email protected]

Conclusion

The unfolding situation surrounding Actinium Pharmaceuticals, Inc. serves as a reminder of the importance of shareholder vigilance and legal recourse in the face of alleged corporate misrepresentation. Investors should ensure they remain informed about their rights and the potential implications of this lawsuit, especially as the deadline for action nears.